---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-249725"
form_type: "8-K"
ticker: "EIKN"
cik: "0001861123"
company_name: "Eikon Therapeutics, Inc."
filed_at: "2026-06-01T11:30:25+00:00"
generated_at: "2026-06-01T11:35:37.963946+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Eikon reports 63.1% ORR in Phase 2 NSCLC trial of EIK1001; PARP1 inhibitor EIK1003 shows 24.5% ORR with paclitaxel

## Summary
- TeLuRide-005 Phase 2: ORR 63.1%, DCR 90.8% in 1L stage 4 NSCLC (n=65 evaluable).
- Non-squamous cohort: ORR 55.6%, DCR 83.3%, median DOR >11 months at 13.6 months follow-up.
- Squamous cohort: ORR 72.4%, DCR 100% with median follow-up 8.8 months (data maturing).
- EIK1003 monotherapy (Cohort 1A): ORR 14.3% overall (26.7% PARP-naïve), median DOR 7.8 months in responders.
- EIK1003 + paclitaxel (Cohort 1C): ORR 24.5% (29.6% in platinum-resistant ovarian, 19.2% in breast).

## SEC filing metadata
- accession: 0001193125-26-249725
- form_type: 8-K
- ticker: EIKN
- cik: 0001861123
- company_name: Eikon Therapeutics, Inc.
- filed_at: 2026-06-01T11:30:25+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1861123/000119312526249725/0001193125-26-249725-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1861123/000119312526249725/eikn-20260530.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-249725
- JSON: https://secwatch.observer/filing/0001193125-26-249725.json
- Plain text: https://secwatch.observer/filing/0001193125-26-249725.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.